UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Journal of medicinal chemistry, 2020-07, Vol.63 (13), p.6648-6676

2020

Volltextzugriff (PDF)

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy

Journal of medicinal chemistry, 2019-05, Vol.62 (9), p.4401-4410

2019

Volltextzugriff (PDF)

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma

mAbs, 2024, Vol.16 (1), p.2310248-2310248

2024

Volltextzugriff (PDF)

SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma

Molecular oncology, 2023-02, Vol.17 (2), p.284-297

2023

Volltextzugriff (PDF)

Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase

Bioorganic & medicinal chemistry letters, 2013-03, Vol.23 (6), p.1588-1591

2013

Volltextzugriff (PDF)

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

Cancer research (Chicago, Ill.), 2006-01, Vol.66 (2), p.951-959

2006

Volltextzugriff (PDF)

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Volltextzugriff (PDF)

Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents

Clinical cancer research, 1999-06, Vol.5 (6), p.1569-1582

1999

Volltextzugriff (PDF)

Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Apoptosis-inducing Anticancer Agent

Clinical cancer research, 2000-04, Vol.6 (4), p.1546-1556

2000

Volltextzugriff (PDF)

Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes

Journal of inorganic biochemistry, 2000-03, Vol.78 (4), p.321-330

2000

Volltextzugriff (PDF)

Apoptosis-inducing Vanadocene Compounds against Human Testicular Cancer

Clinical cancer research, 2000-04, Vol.6 (4), p.1536-1545

2000

Volltextzugriff (PDF)

Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Antileukemic Agent with Matrix Metalloproteinase Inhibitory Activity

Clinical cancer research, 2001-04, Vol.7 (4), p.1094-1101

2001

Volltextzugriff (PDF)

In Vivo Antitumor Activity of Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) {METVAN [VO(SO4)(Me2-Phen)2]}

Clinical cancer research, 2001-07, Vol.7 (7), p.2124-2133

2001

Volltextzugriff (PDF)

Molecular Genotoxicity Profiles of Apoptosis-Inducing Vanadocene Complexes

Toxicology and applied pharmacology, 1999-02, Vol.154 (3), p.228-235

1999

Volltextzugriff (PDF)

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.473-489

2022

Volltextzugriff (PDF)

Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells

Clinical cancer research, 1998-04, Vol.4 (4), p.901-912

1998

Volltextzugriff (PDF)

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Journal of medicinal chemistry, 2017-11, Vol.60 (21), p.8989-9002

2017

Volltextzugriff (PDF)

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1727-1738

2018

Volltextzugriff (PDF)

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity

Journal of medicinal chemistry, 2021-09, Vol.64 (17), p.12670-12679

2021

Volltextzugriff (PDF)

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G 1 -S Checkpoint

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1727

2018

Volltextzugriff (PDF)

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor

Clinical cancer research, 1998-05, Vol.4 (5), p.1125-1134

1998

Volltextzugriff (PDF)

Abstract 4517: Evaluation of the TOR kinase inhibitor CC214-2 in a mouse model of hormone-refractory prostate cancer

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4517-4517

2014

Volltextzugriff (PDF)

Organic phenyl arsonic acid compounds with potent antileukemic activity

Bioorganic & medicinal chemistry letters, 2003-02, Vol.13 (3), p.581-583

2003

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Humans
(36)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Oncology
(22)
Tumor Cells, Cultured
(22)
Antineoplastic Agents - Pharmacology
(21)
Pharmacology. Drug Treatments
(21)
Antineoplastic Agents
(20)
Pharmacology & Pharmacy
(19)
Animals
(18)
Chemistry, Medicinal
(16)
Chemotherapy
(13)
Apoptosis
(12)
Mice
(11)
Chemistry
(10)
Physical Sciences
(10)
Antineoplastic Agents - Chemistry
(9)
Dose-Response Relationship, Drug
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma

Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Structure-based Design of Specific Inhibitors of Janus Kinase 3 as Apoptosis-inducing Antileukemic Agents

Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Apoptosis-inducing Anticancer Agent

Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes

Apoptosis-inducing Vanadocene Compounds against Human Testicular Cancer

Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) as a Novel Antileukemic Agent with Matrix Metalloproteinase Inhibitory Activity

In Vivo Antitumor Activity of Bis(4,7-dimethyl-1,10-phenanthroline) Sulfatooxovanadium(IV) {METVAN [VO(SO4)(Me2-Phen)2]}

Molecular Genotoxicity Profiles of Apoptosis-Inducing Vanadocene Complexes

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1–S Checkpoint

Structure-Guided Optimization Provides a Series of TTK Protein Inhibitors with Potent Antitumor Activity

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G 1 -S Checkpoint

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor

Abstract 4517: Evaluation of the TOR kinase inhibitor CC214-2 in a mouse model of hormone-refractory prostate cancer

Organic phenyl arsonic acid compounds with potent antileukemic activity

Suchergebnisse filtern